Post by
oxinos on Nov 28, 2020 8:48am
We lost our focus
A while back we were so excited about the gold nanorod technology and it's unlimited uses in the health sciences. But we were focused exclusively on one thing. On Sona's lateral flow antigen test and when we met road blocks on the way to approval from FDA and HC our world fell apart as if all other prospects of the patent application for the gold nanorod technology and it's many uses did not exist anymore. The sell off for this temporary delay was immense. The lateral flow antigen test was the tree that blocked our view of the forest, (the many uses of the nanorod technology), was all but forgotten. We need to pull back from the antigen test tree so that we can see the forest. The company still has the CTAB free nanorod technology that can be used in drug delivery for targeted cancer treatment and host of other uses that has the potential to change the methods of treatments. When someone trips up and falls to the ground does he stay down? No. He gets back up. That is how it will be for Sona. The company stumbled in its quest for approval of its lateral flow antigen test. They didn't give up. It will take a little while longer. The value in this company is not the antigen test but the disruptive technology that it has and the variety of uses that it can applied to.